Alnylam Pharmaceuticals ALNY Research Services Obligation — Deferred Revenue

Similar metrics at other companies

NUVBResearch And Development Service Revenue — Deferred Revenue

$300K—

SDGRSoftware products and services — Deferred Revenue

$52.31M+10.5%

TXGProducts and Services, Excluding Grant Revenue — Deferred Revenue

$24.3M+16.3%

IBT

IBTADeferred revenue — Deferred Revenue

$2.7M-51.8%

MCOMoodys Investors Service — Deferred Revenue

$295M+0.3%

NVAXTransition Services — Deferred Revenue

$900K-91.6%

FAQ

What is Alnylam Pharmaceuticals's research services obligation — deferred revenue?

Alnylam Pharmaceuticals (ALNY) reported research services obligation — deferred revenue of $4M in Q2 2026.

How has Alnylam Pharmaceuticals's research services obligation — deferred revenue changed year-over-year?

Alnylam Pharmaceuticals's research services obligation — deferred revenue decreased by 73.5% year-over-year, from $15.08M to $4M.

What is the long-term trend for Alnylam Pharmaceuticals's research services obligation — deferred revenue?

Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's research services obligation — deferred revenue has grown at a -27.1% compound annual growth rate (CAGR), from $175.8M to $49.77M.

What does research services obligation — deferred revenue mean?

Represents the portion of the transaction price for research services that has been billed or collected but not yet recognized as revenue because the performance obligations remain unsatisfied. This liability reflects future research work that the company is contractually obligated to perform. A high balance indicates a significant backlog of research activities to be completed.